These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20947317)

  • 1. Effects of behavioral therapy or pharmacotherapy on brain glucose metabolism in subjects with obsessive-compulsive disorder as assessed by brain FDG PET.
    Apostolova I; Block S; Buchert R; Osen B; Conradi M; Tabrizian S; Gensichen S; Schröder-Hartwig K; Fricke S; Rufer M; Weiss A; Hand I; Clausen M; Obrocki J
    Psychiatry Res; 2010 Nov; 184(2):105-16. PubMed ID: 20947317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The caudate nucleus in obsessive-compulsive disorder. Reduced metabolism following treatment with paroxetine: a PET study.
    Hansen ES; Hasselbalch S; Law I; Bolwig TG
    Int J Neuropsychopharmacol; 2002 Mar; 5(1):1-10. PubMed ID: 12057027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression.
    Saxena S; Brody AL; Ho ML; Zohrabi N; Maidment KM; Baxter LR
    Am J Psychiatry; 2003 Mar; 160(3):522-32. PubMed ID: 12611834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression.
    Saxena S; Brody AL; Ho ML; Alborzian S; Maidment KM; Zohrabi N; Ho MK; Huang SC; Wu HM; Baxter LR
    Arch Gen Psychiatry; 2002 Mar; 59(3):250-61. PubMed ID: 11879163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder.
    Saxena S; Brody AL; Maidment KM; Dunkin JJ; Colgan M; Alborzian S; Phelps ME; Baxter LR
    Neuropsychopharmacology; 1999 Dec; 21(6):683-93. PubMed ID: 10633474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebral glucose metabolism in obsessive-compulsive hoarding.
    Saxena S; Brody AL; Maidment KM; Smith EC; Zohrabi N; Katz E; Baker SK; Baxter LR
    Am J Psychiatry; 2004 Jun; 161(6):1038-48. PubMed ID: 15169692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder.
    Schwartz JM; Stoessel PW; Baxter LR; Martin KM; Phelps ME
    Arch Gen Psychiatry; 1996 Feb; 53(2):109-13. PubMed ID: 8629886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid effects of brief intensive cognitive-behavioral therapy on brain glucose metabolism in obsessive-compulsive disorder.
    Saxena S; Gorbis E; O'Neill J; Baker SK; Mandelkern MA; Maidment KM; Chang S; Salamon N; Brody AL; Schwartz JM; London ED
    Mol Psychiatry; 2009 Feb; 14(2):197-205. PubMed ID: 18180761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain serotonin synthesis capacity in obsessive-compulsive disorder: effects of cognitive behavioral therapy and sertraline.
    Lissemore JI; Sookman D; Gravel P; Berney A; Barsoum A; Diksic M; Nordahl TE; Pinard G; Sibon I; Cottraux J; Leyton M; Benkelfat C
    Transl Psychiatry; 2018 Apr; 8(1):82. PubMed ID: 29666372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intensive cognitive-behavioral therapy on cingulate neurochemistry in obsessive-compulsive disorder.
    O'Neill J; Gorbis E; Feusner JD; Yip JC; Chang S; Maidment KM; Levitt JG; Salamon N; Ringman JM; Saxena S
    J Psychiatr Res; 2013 Apr; 47(4):494-504. PubMed ID: 23290560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome in adults with obsessive-compulsive disorder.
    Bloch MH; Green C; Kichuk SA; Dombrowski PA; Wasylink S; Billingslea E; Landeros-Weisenberger A; Kelmendi B; Goodman WK; Leckman JF; Coric V; Pittenger C
    Depress Anxiety; 2013 Aug; 30(8):716-22. PubMed ID: 23532944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls.
    Baxter LR; Phelps ME; Mazziotta JC; Guze BH; Schwartz JM; Selin CE
    Arch Gen Psychiatry; 1987 Mar; 44(3):211-8. PubMed ID: 3493749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [
    Lee J; Kim BH; Kim E; Howes OD; Cho KIK; Yoon YB; Kwon JS
    Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29210107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
    Tundo A; Salvati L; Busto G; Di Spigno D; Falcini R
    J Clin Psychiatry; 2007 Oct; 68(10):1552-6. PubMed ID: 17960971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic imaging of bilateral anterior capsulotomy in refractory obsessive compulsive disorder: an FDG PET study.
    Zuo C; Ma Y; Sun B; Peng S; Zhang H; Eidelberg D; Guan Y
    J Cereb Blood Flow Metab; 2013 Jun; 33(6):880-7. PubMed ID: 23443174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram.
    Carey PD; Warwick J; Niehaus DJ; van der Linden G; van Heerden BB; Harvey BH; Seedat S; Stein DJ
    BMC Psychiatry; 2004 Oct; 4():30. PubMed ID: 15482603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basolateral amygdala-ventromedial prefrontal cortex connectivity predicts cognitive behavioural therapy outcome in adults with obsessive-compulsive disorder.
    Fullana MA; Zhu X; Alonso P; Cardoner N; Real E; López-Solà C; Segalàs C; Subirà M; Galfalvy H; Menchón JM; Simpson HB; Marsh R; Soriano-Mas C
    J Psychiatry Neurosci; 2017 Nov; 42(6):378-385. PubMed ID: 28632120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors associated with improved cognitive-behavioral therapy outcome in pediatric obsessive-compulsive disorder.
    Torp NC; Dahl K; Skarphedinsson G; Compton S; Thomsen PH; Weidle B; Hybel K; Valderhaug R; Melin K; Nissen JB; Ivarsson T
    J Am Acad Child Adolesc Psychiatry; 2015 Mar; 54(3):200-207.e1. PubMed ID: 25721185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial.
    Franklin ME; Sapyta J; Freeman JB; Khanna M; Compton S; Almirall D; Moore P; Choate-Summers M; Garcia A; Edson AL; Foa EB; March JS
    JAMA; 2011 Sep; 306(11):1224-32. PubMed ID: 21934055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How resistant is 'treatment-resistant' obsessive-compulsive disorder in youth?
    Krebs G; Isomura K; Lang K; Jassi A; Heyman I; Diamond H; Advani J; Turner C; Mataix-Cols D
    Br J Clin Psychol; 2015 Mar; 54(1):63-75. PubMed ID: 25130442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.